マルチオミクスを用いた最新創薬手法

Highlight Illumina’s vision to build a single Comprehensive Genomic Profiling (CGP) CDx solution for global markets. In the presentation, I will articulate the path to evolve testing infrastructure, gain broad patient access, and how strategic partnerships will help evolve and grow a changing global healthcare landscape in genomic testing.

The application of multi-omics has the potential to transform pharmaceutical development in a time where new drug approvals for asthma, COPD and other common diseases remain low. Taking a Precision Medicine approach to find the Right Patient is part of the solution. By leveraging the worlds genomic data to find new targets and precision medicine strategies, exploiting large phenotyped patient cohorts to understand disease drive and heterogeniety, and accessing target tissue non-invasively to enable longitudinal monitoring of disease activity and drug response, we can change the target paradigm, linking the right target to the right patient from the start.